Compare · PCSA vs SBFM

PCSA vs SBFM

Side-by-side comparison of Processa Pharmaceuticals Inc. (PCSA) and Sunshine Biopharma Inc. (SBFM): market cap, price performance, sector, and recent activity on the wire.

Summary

  • Both PCSA and SBFM operate in Biotechnology: Pharmaceutical Preparations (Health Care), so they compete in similar markets.
  • PCSA is the larger of the two at $5.2M, about 2.3x SBFM ($2.2M).
  • PCSA has been more active in the news (10 items in the past 4 weeks vs 5 for SBFM).
  • PCSA has more recent analyst coverage (3 ratings vs 0 for SBFM).
MetricPCSASBFM
Company
Processa Pharmaceuticals Inc.
Sunshine Biopharma Inc.
Price
-
-
Market cap
$5.2M
$2.2M
1M return
+4.48%
-
1Y return
-74.50%
-
Industry
Biotechnology: Pharmaceutical Preparations
Biotechnology: Pharmaceutical Preparations
Exchange
NASDAQ
NASDAQ
IPO
News (4w)
10
5
Recent ratings
3
0
PCSA

Processa Pharmaceuticals Inc.

Processa Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, focuses on the development of drug products for the treatment of patients with unmet medical needs in the United States. Its lead product candidate is PCS499, an oral tablet that is in Phase II clinical trials for the treatment of necrobiosis lipoidica, a chronic disfiguring condition. The company is also developing PCS12852, a novel selective 5-hydroxytryptamine 4 (5-HT4) receptor agonist that is in Phase II clinical trials for the treatment of gastroparesis; and PCS6422, an oral, potent, selective, and irreversible inhibitor that is in Phase I clinical trials for treating metastatic colorectal and breast cancer. It has a license agreement with Akashi Therapeutics, Inc. to develop and commercialize PCS100, an anti-fibrotic and anti-inflammatory drug. The company was incorporated in 2011 and is based in Hanover, Maryland.

SBFM

Sunshine Biopharma Inc.

Sunshine Biopharma, Inc., a pharmaceutical and nutritional supplement company, focuses on the research and development of anticancer drugs. The company is developing Adva-27a, a GEM-difluorinated C-glycoside derivative of podophyllotoxin to treat leukemia, lymphoma, testicular, lung, brain, prostate, bladder, colon, ovarian, liver, and other forms of cancers, as well as kills multidrug resistant cancer cells, including pancreatic cancer, breast cancer, small-cell lung cancer, and uterine sarcoma cells; and SBFM-PL4, an anti-coronavirus treatment compound. It also offers Essential 9, a nutritional supplement tablet; and Calcium-Vitamin D supplement under the Essential Calcium-Vitamin D brand name, as well as develops and markets other science-based nutritional supplements. The company has a license agreement with the University of Georgia to advance the development of its anti-coronavirus lead compound, SBFM-PL4. Sunshine Biopharma, Inc. is headquartered in Pointe-Claire, Canada.